Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Belgium / NCT05900778
Recruiting Not applicable

Implementation of a HABIT-ILE Intervention at William Lennox Neurological Hospital (NeuREHA)

NCT05900778 · tracked via the Priya Life Science Belgium tracker
Sponsor
Université Catholique de Louvain
Phase
Not applicable
Started
2023-06-10
Last updated
2023-06-18

Condition(s) studied

Acquired Brain Injury

Investigational drug(s) / intervention(s)

HABIT-ILEConventional intervention

HABIT-ILE: 2 weeks HABIT-ILE

Conventional intervention: 2 weeks usual intervention (waitlist group)

Study summary

Using a randomized controlled trial design, in an hospital environment, possible changes induced by the "Hand-arm Bimanual Intensive Therapy Including Lower Extremities (HABIT-ILE)" treatment program will be investigated in functional activities of daily living, motor and cognitive assessment of children with acquired brain injury.

Eligibility

Sex
ALL
Min age
5 Years
Max age
18 Years
Healthy volunteers
No
Inclusion Criteria: * children with acquired brain injury of school * age 5 to 18 years inclusive Exclusion Criteria: * Unstable seizure * programmed botulinum toxin or orthopedic surgery in the 6 months previous to the intervention, during intervention period or 3months after the intervention time * Severe visual or cognitive impairments likely to interfere with intervention or testing session completion

Primary outcome measure(s)

  • Flanker task — T0 (baseline), T1 (after 2weeks intervention), T2(3 months follow-up)
    Cognitive functions of the children will be assessed by Flanker task.
  • Changes in Gross Motor Function Measurement (GMFM 66) — T0 (baseline), T1 (after 2weeks intervention), T2(3 months follow-up)
    The GMFM has been developed to measure the change in gross motor function over time in children with cerebral palsy.

Trial sites (3)

FacilityCityRegionStatus
Centre Hospitalier Neurologique William Lennox Ottignies-Louvain-la-Neuve Brabant-Wallon Recruiting
Institute of Neurosciences, UCLouvain Brussels Belgium Recruiting
Spontaneous contact via doctors or other partners Brussels Belgium Recruiting

More Université Catholique de Louvain trials in Belgium

Implementation of a HABIT-ILE Intervention at William Lennox Neurological Hospital (NeuREHA) - Adult Starting soon
Implementation of a HABIT-ILE Intervention at Home for Children With Bilateral Cerebral Palsy Recruiting
Birth Experience of Women Giving Birth in Belgium Recruiting
A Geriatric Mobile Team for Nursing Home Residents: a Feasibility Pilot Study Starting soon
Bridging the Gap: Implementing BRIDGES Enrolling by invitation

Other trials for the same condition

Evaluation of Macroscopic Muscle Growth in Infants and Young Children With Spastic Cerebral Palsy Recruiting
Comparing the Ceriter Stride One, a Pressure-sensitive Smart Insole, With Gait Parameters Measured on the GRAIL in Neurological Populations Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05900778 on ClinicalTrials.gov ↗ ← All trials in Belgium